Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistance

Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistance

Colorectal cancer (CRC) patients with BRAF mutations develop resistance to BRAF inhibitors at a very early stage. Understanding the molecular mechanisms involved in BRAF inhibitor resistance is critical for the development of novel therapeutic opportunities for this subtype of CRC patients. CRC cell...

Full description

Bibliographic Details
Main Authors: Angelina Pranteda, Valentina Piastra, Martina Serra, Roberta Bernardini, Federica Lo Sardo, Silvia Carpano, Maria Grazia Diodoro, Armando Bartolazzi, Michele Milella, Giovanni Blandino, Gianluca Bossi
Format: Article
Language:English
Published: Elsevier 2023-11-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Colorectal Cancer (CRC)
MKK3 / p38MAPK
MYC
BRAF target therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223012787

Internet

http://www.sciencedirect.com/science/article/pii/S0753332223012787

Similar Items